Alcohol

Abacavir [1], alcohol ---> SmPC of [1] of EMA

The metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%. These findings are not considered clinically significant.

Abacavir/lamivudine [1], alcohol ---> SmPC of [1] of EMA

Increase of the AUC of abacavir by inhibition of alcohol dehydrogenase. No dosage adjustment necessary.

Abacavir/lamivudine/zidovudine [1], alcohol ---> SmPC of [1] of EMA

Increase of the AUC of abacavir by inhibition of alcohol dehydrogenase. No dosage adjustment necessary.

ACE inhibitors, alcohol ---> SmPC of [enalapril] of eMC

Alcohol enhances the hypotensive effect of ACE inhibitors.

Acemetacine, alcohol

Enhancement of the adverse effects of the NSAID, especially those of the gastrointestinal tract and CNS

Acenocoumarol [1], alcohol ---> SmPC of [1] of eMC

Since it is not possible to predict the severity of any drug interactions, patients should limit their alcohol intake

Acetylsalicylic acid [1], alcohol ---> SmPC of [1] of eMC

The co-administration of alcohol with acetylsalicylic acid increases the risk of gastrointestinal bleeding

Acitretin [1], alcohol ---> SmPC of [1] of eMC

The co-administration produces etretinate, which is very teratogen

Adrenaline, alcohol

The effects of adrenaline may be potentiated by alcohol

Agomelatine [1], alcohol ---> SmPC of [1] of EMA

The combination of Valdoxan and alcohol is not advisable

Alaproclate, alcohol

It is recommended to avoid alcohol use while taking SSRI

Alcohol, alfentanyl [2] ---> SmPC of [2] of eMC

CNS depressants may enhance or prolong the respiratory depressant effects of alfentanil.

Alcohol, alimemazine [2] ---> SmPC of [2] of eMC

The sedative effects of phenothiazines may be intensified (additively) by alcohol

Alcohol, aliskiren/amlodipine/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Concomitant administration of thiazide diuretics with subtances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Alcohol, aliskiren/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Concomitant administration of thiazide diuretics with subtances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Alcohol, alizapride

Increased CNS depressant effect

Alcohol, alogliptin/metformin [2] ---> SmPC of [2] of EMA

The concomitant intake of alcohol may enhance the hypoglycemic effect of metformin until hypoglycaemic shock. Alcohol and drugs containing alcohol should be avoided

Alcohol, alprazolam [2] ---> SmPC of [2] of eMC

Benzodiazepines produce an additive effect when co-administered with alcohol

Alcohol, amantadine

Decreased alcohol tolerance. The co-administration should be avoided

Alcohol, amiloride/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Co-administration with alcohol may potentiate orthostatic hypotension.

Alcohol, amisulpride [2] ---> SmPC of [2] of eMC

Amisulpride may enhance the central effects of alcohol. Concomitant use is not recommended

Alcohol, amitriptyline [2] ---> SmPC of [2] of eMC

Enhances the sedative effect.

Alcohol, amitriptylinoxide

The combination may potentiate the effect of amitriptylinoxide

Alcohol, amlodipine/valsartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Alcohol, anticholinergics

Anticholinergic drugs may enhance the depressive effect of alcohol on the central nervous system

Alcohol, antidepressants

Alcohol intake is not advisable during antidepressant treatment

Alcohol, antiepileptics

Alcohol may decrease or abolish the antiepileptic effect

Alcohol, antihistamines ---> SmPC of [mequitazine] of eMC

Antihistamines potentiate the sedative effects of alcohol

Alcohol, antihypertensives ---> SmPC of [lercanidipine] of eMC

Alcohol should be avoided since it may potentiate the effect of vasodilating antihypertensive drugs.

Alcohol, apraclonidine [2] ---> SmPC of [2] of eMC

The possibility of an additive or potentiating effect with CNS depressants should be considered.

Alcohol, aripiprazole [2] ---> SmPC of [2] of EMA

Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol

Alcohol, asenapine [2] ---> SmPC of [2] of EMA

Patients should be advised to avoid alcohol while taking Sycrest.

Alcohol, atenolol/chlortalidone

Enhanced antihypertensive effect

Alcohol, atropine

Anticholinergic drugs may enhance the depressive effect of alcohol on the central nervous system

Alcohol, avanafil [2] ---> SmPC of [2] of EMA

Consumption of alcohol in combination with avanafil can increase the potential for symptomatic hypotension.

Alcohol, azelastine

Azelastine may enhance sedation effects of other medicinal products as tranquilizers, hypnotics and alcohol

Alcohol, baclofen [2] ---> SmPC of [2] of eMC

The concomitant intake of alcohol and baclofen should be avoided as the interactions with alcohol are unpredictable.

Alcohol, bamethane

Possible enhancement of sympathomimetic effect

Alcohol, barbiturates

The co-administration may mutually enhance the CNS depressant effects

Alcohol, barnidipine

The co-administration may increase the antihypertensive effect. Alcohol consumption should be avoided

Alcohol, beclometasone/formoterol/glycopyrronium [2] ---> SmPC of [2] of EMA

L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards beta2-sympathomimetics.

Alcohol, bedaquiline [2] ---> SmPC of [2] of EMA

Alcohol should be avoided while on bedaquiline

Alcohol, benazepril

Enhancement of hypotension and effect of alcohol

Alcohol, benazepril/hydrochlorothiazide ---> SmPC of [enalapril] of eMC

Alcohol enhances the hypotensive effect of ACE inhibitors.

Alcohol, bendroflumethiazide [2] ---> SmPC of [2] of eMC

Postural hypotension may be enhanced by concomitant ingestion of alcohol

Alcohol, benperidol

Benperidol can increase the CNS depression produced by other CNS-depressant drugs

Alcohol, benzodiazepines

The co-administration may cause a mutual potentiation of the depressor effect on the CNS. Alcohol consumption should be avoided

Alcohol, benzylpenicillin

The co-administration may inactivate benzylpenicillin

Alcohol, betablockers [2] ---> SmPC of [2] of eMC

Alcohol induces increased plasma levels of hepatically metabolised beta blockers

Alcohol, biperiden

Biperiden may increase the alcohol effect (alcohol avoid)

Alcohol, bisoprolol [2] ---> SmPC of [2] of eMC

The effect of bisoprolol can be potentiated by alcohol

Alcohol, bornaprine

Bornaprine may increase the alcohol effect

Alcohol, brimonidine [2] ---> SmPC of [2] of EMA

The possibility of an additive or potentiating effect with CNS depressants should be considered.

Alcohol, brinzolamide/brimonidine [2] ---> SmPC of [2] of EMA

Caution is advised due to the possibility of an additive or potentiating effect of brinzolamide/brimonidine with CNS depressants

Alcohol, brivaracetam [2] ---> SmPC of [2] of EMA

Brivaracetam approximately doubled the effect of alcohol on psychomotor function, attention and memory. Intake of brivaracetam with alcohol is not recommended.

Alcohol, bromazepam

Enhancement of the depressor effect on the central nervous system

Alcohol, bromocriptine [2] ---> SmPC of [2] of eMC

Tolerance to bromocriptine may be reduced by alcohol.

Alcohol, bromperidol

The co-administration may increase the alcohol effect and decrease the blood pressure

Alcohol, brotizolam

Concomitant intake with alcohol should be avoided due to the effect of brotizolam may be altered or potentiated in an unpredictable way

Alcohol, budesonide/formoterol [2] ---> SmPC of [2] of EMA

Alcohol can impair cardiac tolerance towards beta2 sympathomimetics.

Alcohol, buflomedil

The co-administration may increase the hypotensive effect

Alcohol, buprenorphine [2] ---> SmPC of [2] of EMA

Buprenorphine should be used cautiously when co-administered with alcoholic drinks or medicinal products containing alcohol as alcohol increases the sedative effect of buprenorphine

Alcohol, buprenorphine/naloxone [2] ---> SmPC of [2] of EMA

Alcohol increases the sedative effect of buprenorphine. Buprenorphine should not be taken together with alcoholic drinks or medications containing alcohol

Alcohol, bupropion [2] ---> SmPC of [2] of eMC

The consumption of alcohol during bupropion treatment should be minimized or avoided.

Alcohol, buspirone

Alcohol consumption should be avoided

Alcohol, butyrophenones

Additive effect

Alcohol, cabergoline [2] ---> SmPC of [2] of eMC

The effects of alcohol on overall tolerability of cabergoline are currently unknown.

Alcohol, caffeine

Caffeine does not compensate the adverse effects of alcohol on performance, in isolated cases there is a risk of accelerated absorption of alcohol.

Alcohol, canagliflozin/metformin [2] ---> SmPC of [2] of EMA

There is increased risk of lactic acidosis in acute alcohol intoxication due to the metformin active substance of this medicinal product. Consumption of alcohol and medicinal products containing alcohol should be avoided.

Alcohol, cannabidiol [2] ---> SmPC of [2] of EMA

Other CNS depressants, including alcohol, can potentiate the somnolence and sedation effect.

Alcohol, captopril

Additive effect

Alcohol, carbamazepine [2] ---> SmPC of [2] of eMC

Carbamazepine may reduce alcohol tolerance. It is therefore advisable for the patient to abstain from alcohol.

Alcohol, cariprazine [2] ---> SmPC of [2] of EMA

Given the primary central nervous system effects of cariprazine, Reagila should be used with caution in combination with other centrally acting medicinal products and alcohol.

Alcohol, carvedilol [2] ---> SmPC of [2] of eMC

Carvedilol may potentiate the effects of medicines with antihypertensive adverse reactions such as alcohol

Alcohol, ceftriaxone [2] ---> SmPC of [2] of eMC

No effect similar to that of disulfiram has been demonstrated after ingestion of alcohol subsequent to the administration of ceftriaxone.

Alcohol, celiprolol

Increased hypotensive effect

Alcohol, cenobamate [2] ---> SmPC of [2] of EMA

Concomitant use of cenobamate with other CNS depressants, including alcohol, barbiturates, and benzodiazepines may increase the risk of neurological adverse reactions.

Alcohol, cetirizine

Increased CNS depressant effect

Alcohol, chlomethiazole

The concomitant intake of alcohol may have life threatening effects

Alcohol, chloral hydrate [2] ---> SmPC of [2] of eMC

Alcohol potentiates the sedative effect.

Alcohol, chloramphenicol

The combination may cause intolerance

Alcohol, chlordiazepoxide [2] ---> SmPC of [2] of eMC

Chlordiazepoxide should not be used together with alcohol (enhanced sedative effects)

Alcohol, chlorphenamine [2] ---> SmPC of [2] of eMC

Chlorphenamine may have an additive effect when used concurrently with alcohol causing potentiation of drowsiness.

Alcohol, chlorpromazine [2] ---> SmPC of [2] of eMC

Alcohol enhances the sedative effect of neuroleptics. Association not recommended

Alcohol, chlorprothixene

The co-administration of alcohol with chlorprothixene may increase the alcohol effect and decrease the blood pressure

Alcohol, chlortalidone

The co-administration may increase the antihypertensive effects

Alcohol, cilazapril

Increased effect of alcohol

Alcohol, cimetidine

Cimetidine increases the alcohol effect

Alcohol, cinitapride

The co-administration enhances the sedative effects

Alcohol, cinnarizine [2] ---> SmPC of [2] of eMC

Concurrent use of cinnarizine and alcohol may potentiate the sedative effects

Alcohol, citalopram [2] ---> SmPC of [2] of eMC

The combination of citalopram and alcohol is not advisable.

Alcohol, clebopride

Clebopride may enhance the sedative effects

Alcohol, clemastine [2] ---> SmPC of [2] of eMC

Antihistamines potentiate the sedative effects of alcohol

Alcohol, clobazam [2] ---> SmPC of [2] of eMC

Alcohol can increase the bioavailability of clobazam. Enhancement of the central depressive effect may occur

Alcohol, clomipramine [2] ---> SmPC of [2] of eMC

Tricyclic antidepressants may potentiate the effects of alcohol

Alcohol, clonazepam [2] ---> SmPC of [2] of eMC

In combination with clonazepam, alcohol may modify the effects of the drug, compromise the success of therapy or give rise to unpredictable side-effects

Alcohol, clonidine [2] ---> SmPC of [2] of eMC

The effect of alcohol could theoretically be potentiated by clonidine.

Alcohol, clopamide

Increased hypotensive effect

Alcohol, cloperastine

Cloperastine may enhance the effects of alcohol

Alcohol, clopidogrel/acetylsalicylic acid [2] ---> SmPC of [2] of EMA

Patients should be counseled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy.

Alcohol, clozapine [2] ---> SmPC of [2] of eMC

Alcohol should not be used concomitantly with clozapine due to possible potentiation of sedation.

Alcohol, CNS depressants

It is recommended not to take alcohol due to additive depressive effect on the central nervous system

Alcohol, coagulation factor IIa

Denaturation

Alcohol, codeine [2] ---> SmPC of [2] of eMC

Enhanced sedative and hypotensive effect, increased risk of respiratory depression

Alcohol, colchicine

The co-administration may increase the colchicine toxicity

Alcohol, coumarin anticoagulants

The acute/chronic alcohol intake enhances/decreases the anticoagulant effect

Alcohol, cyclophosphamide

It is recommended not to take alcohol

Alcohol, cyproheptadine [2] ---> SmPC of [2] of eMC

Antihistamines may have additive effects with alcohol

Alcohol, cyproterone

The sexual drive reducing effect of cyproterone can be diminished under the influence of alcohol

Alcohol, dacarbazine [2] ---> SmPC of [2] of eMC

Alcohol should be avoided during chemotherapy.

Alcohol, danazol [2] ---> SmPC of [2] of eMC

Subjective intolerance in the form of nausea and shortness of breath has been reported.

Alcohol, dantrolene

The co-administration of dantrolene and alcohol should be avoided due to the adverse reactions of dantrolene may be enhanced

Alcohol, dapagliflozin/metformin [2] ---> SmPC of [2] of EMA

There is increased risk of lactic acidosis in acute alcohol intoxication due to the metformin active substance of this medicinal product. Consumption of alcohol and medicinal products containing alcohol should be avoided.

Alcohol, dapoxetine [2] ---> SmPC of [2] of eMC

Patients should be advised to avoid alcohol while taking dapoxetine

Alcohol, delapril

Alcohol increases the hypotensive effect

Alcohol, desloratadine [2] ---> SmPC of [2] of EMA

Cases of alcohol intolerance and intoxication have been reported during post marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.

Alcohol, desloratadine/pseudoephedrine [2] ---> SmPC of [2] of EMA

Alcohol use should be avoided during desloratadine/pseudoephedrine treatment.

Alcohol, dexchlorpheniramine

The combination of dexchlorpheniramine with other CNS depressants may enhance the CNS depressant effect

Alcohol, dextromethorphan

Alcohol intake during the treatment with dextromethorphan may increase the adverse reactions. It should not be taken together with alcoholic drinks

Alcohol, dextromethorphan/quinidine [2] ---> SmPC of [2] of EMA

Caution should be used when this medicinal product is taken in combination with alcohol or other centrally acting medicinal products that might increase the risk of adverse reactions such as somnolence and dizziness.

Alcohol, diamorphine [2] ---> SmPC of [2] of eMC

Alcohol may enhance the sedative and hypotensive effects of diamorphine.

Alcohol, diazepam [2] ---> SmPC of [2] of eMC

Diazepam should not be used together with alcohol (enhanced sedative effects)

Alcohol, diazoxide

Diazoxide may potentiate the effect of hypotensive drugs, what cause a further hypotension

Alcohol, dihexazin

The concomitant use should be avoided

Alcohol, dihydralazine

The co-administration may enhance the hypotensive and hypnotic effect

Alcohol, dihydrocodeine [2] ---> SmPC of [2] of eMC

The hypotensive, sedative and respiratory depressive effects of alcohol may be enhanced; alcohol should be avoided.

Alcohol, dihydroergotamine

The concomitant intake of alcohol should be avoided

Alcohol, dimenhydrinate

Dimenhydrinate may increase the effects of other CNS depressors and enhance the sedative effects

Alcohol, dimethindene

The sedative effect of CNS depressant drugs may be enhanced

Alcohol, dimethyl fumarate [2] ---> SmPC of [2] of EMA

Consumption of large quantities of undiluted strong alcoholic drinks may increase the frequency of gastrointestinal adverse reactions.

Alcohol, diphenhydramine [2] ---> SmPC of [2] of eMC

Diphenhydramine has additive effects with alcohol

Alcohol, dipotassium clorazepate

The sedative effect can be enhanced

Alcohol, disulfiram [2] ---> SmPC of [2] of eMC

Disulfiram blocks the metabolism of alcohol and leads to an accumulation of acetaldehyde in the blood stream.

Alcohol, dixyrazine

Dixyrazine enhances the CNS depressant effect of alcohol

Alcohol, docetaxel [2] ---> SmPC of [2] of EMA

The amount of ethanol in Docetaxel may impair the ability to drive or use machines

Alcohol, dolutegravir/abacavir/lamivudine [2] ---> SmPC of [2] of EMA

Increase of the AUC of abacavir by inhibition of alcohol dehydrogenase. No dosage adjustment necessary.

Alcohol, donepezil [2] ---> SmPC of [2] of eMC

The enzymatic induction may decrease the plasma levels of donepezil

Alcohol, doxepin

The co-administration may enhance the central sedative effect

Alcohol, doxycycline [2] ---> SmPC of [2] of eMC

Alcohol may decrease the half-life of doxycycline.

Alcohol, doxylamine

Alcohol intake should be avoided during treatment with doxylamine because alcohol may potentiate the doxylamine action in an unpredictable fashion.

Alcohol, droperidol [2] ---> SmPC of [2] of eMC

Consumption of alcoholic beverages and medicines should be avoided.

Alcohol, duloxetine [2] ---> SmPC of [2] of EMA

Caution is advised when duloxetine is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products

Alcohol, empagliflozin/metformin [2] ---> SmPC of [2] of EMA

There is increased risk of lactic acidosis in acute alcohol intoxication. Consumption of alcohol and medicinal products containing alcohol should be avoided.

Alcohol, enalapril [2] ---> SmPC of [2] of eMC

Alcohol enhances the hypotensive effect of ACE inhibitors.

Alcohol, enalapril/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Alcohol enhances the hypotensive effect of ACE inhibitors. Potentiation of orthostatic hypotension may occur.

Alcohol, epinephrine

The effects of adrenaline may be potentiated by alcohol

Alcohol, ertugliflozin/metformin [2] ---> SmPC of [2] of EMA

Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in cases of fasting, malnutrition or hepatic impairment.

Alcohol, escitalopram [2] ---> SmPC of [2] of eMC

As with other psychotropic medicinal products, the combination of escitalopram with alcohol is not advisable.

Alcohol, esketamine [2] ---> SmPC of [2] of EMA

Concomitant use of Spravato with CNS depressants (e.g., benzodiazepines, opioids, alcohol) may increase sedation, which therefore should be closely monitored.

Alcohol, estradiol ---> SmPC of [estradiol valerate/norgestrel] of eMC

Acute alcohol intake may increase plasma levels of estradiol

Alcohol, estradiol valerate/norgestrel

Acute alcohol intake may increase plasma levels of estradiol

Alcohol, ethosuximide

The alcohol consumption should be avoided during the treatment

Alcohol, ethyl loflazepate

The co-administration may cause a mutual potentiation of the depressor effect on the CNS. Alcohol consumption should be avoided

Alcohol, etomidate [2] ---> SmPC of [2] of eMC

The hypnotic effect of etomidate may be enhanced by alcohol

Alcohol, etoperidone

It is recommended to avoid alcohol use while taking SSRI

Alcohol, felodipine/metoprolol [2] ---> SmPC of [2] of eMC

The concomitant ingestion of alcohol may enhance hypotensive effects.

Alcohol, felodipine/ramipril [2] ---> SmPC of [2] of eMC

Increased vasodilatation. The antihypertensive effect may increase.

Alcohol, fentanyl [2] ---> SmPC of [2] of EMA

The concomitant use of fentanyl with other central nervous system depressants may produce additive depressant effects.

Alcohol, flunarizine

Concomitant use of flunarizine with alcohol, hypnotics or other tranquilizers may enhance the sedative effect of flunarizine

Alcohol, flunitrazepam

The alcohol consumption should be avoided during the treatment

Alcohol, fluoxetine [2] ---> SmPC of [2] of eMC

In formal testing, fluoxetine did not raise blood alcohol levels or enhance the effects of alcohol. However, the combination of SSRI treatment and alcohol is not advisable.

Alcohol, flupentixol [2] ---> SmPC of [2] of eMC

In common with other antipsychotics, flupentixol enhances the response to other CNS depressants.

Alcohol, fluphenazine

The co-administration may cause a mutual potentiation of effects

Alcohol, flupirtine

Flupirtine may enhance the alcohol effect

Alcohol, flurazepam [2] ---> SmPC of [2] of eMC

Concomitant intake with alcohol should be avoided. The sedative effect may be enhanced when the product is used in combination with alcohol.

Alcohol, flurbiprofen

Alcohol may enhance the risk of adverse effects, especially those of the gastrointestinal tract

Alcohol, fluspirilene

Mutual enhancement of effects

Alcohol, flutamide

Alcohol intake should be avoided due to potential liver and renal toxicity

Alcohol, fluvoxamine [2] ---> SmPC of [2] of eMC

As with other psychotropic drugs, patients should be advised to avoid alcohol use while taking fluvoxamine.

Alcohol, folic acid

Drugs that may adversely affect the absorption or metabolism of folic acid may cause statuses of folate deficiency

Alcohol, formoterol ---> SmPC of [budesonide/formoterol] of EMA

Alcohol can impair cardiac tolerance towards beta2 sympathomimetics.

Alcohol, formoterol/glycopyrronium/budesonide [2] ---> SmPC of [2] of EMA

In addition, L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards beta2-sympathomimetics.

Alcohol, fosphenytoin [2] ---> SmPC of [2] of eMC

Acute alcohol intake may increase phenytoin serum levels while chronic alcoholism may decrease serum levels.

Alcohol, furazolidone

Disulfiram-like reaction. The alcohol intake should be avoided

Alcohol, furosemide

The co-administration may enhance the hypotensive effect

Alcohol, glibenclamide [2] ---> SmPC of [2] of EMA

Both acute and chronic alcohol intake, or excessive alcohol ingestion by people who drink occasionally, may attenuate the hypoglycaemic effect of glibenclamide or dangerously potentiate it by delaying its metabolic inactivation.

Alcohol, gliclazide [2] ---> SmPC of [2] of eMC

Alcohol increases the hypoglycaemic reaction (by inhibiting compensatory reactions) that can lead to the onset of hypoglycaemic coma. Avoid alcohol or medicines containing alcohol.

Alcohol, glimepiride [2] ---> SmPC of [2] of eMC

Alcohol intake may potentiate or weaken the hypoglycaemic action of glimepiride in an unpredictable fashion.

Alcohol, glipizide [2] ---> SmPC of [2] of eMC

Alcohol increases in hypoglycaemic reaction which can lead to hypoglycaemic coma.

Alcohol, gliquidone

The co-administration may increase or decrease the hypoglycemic effect of gliquidone

Alcohol, glycerol trinitrate

Alcohol may potentiate the hypotensive effect of the nitroglycerin

Alcohol, glycerol trinitrate [2] ---> SmPC of [2] of eMC

The risk of hypotension and syncope with use of glyceryl trinitrate may be enhanced by alcohol.

Alcohol, griseofulvin

Increased alcohol effect

Alcohol, guanethidine [2] ---> SmPC of [2] of eMC

The anti-hypertensive action of guanethidine may be enhanced by other anti-hypertensive agents.

Alcohol, guanfacin [2] ---> SmPC of [2] of EMA

Caution should be used when Intuniv is administered concomitantly with CNS depressant medicinal products due to the potential for additive pharmacodynamic effects such as sedation and somnolence.

Alcohol, haloperidol

The concomitant use may enhance the alcohol effect and decrease the blood pressure

Alcohol, hemp extract

The alcohol intake should be avoided. Alcohol may have an additive effect on das CNS, leading to a greater risk of falls.

Alcohol, human fibrinogen/human thrombin [2] ---> SmPC of [2] of EMA

Similar to comparable products or thrombin solutions, the product may be denatured after exposure to solutions containing alcohol

Alcohol, human insulin [2] ---> SmPC of [2] of EMA

Alcohol may intensify or reduce the hypoglycaemic effect of insulin.

Alcohol, hyaluronidase

Increased effect of alcohol. The alcohol intake should be avoided

Alcohol, hydralazine [2] ---> SmPC of [2] of eMC

Concurrent treatment of hydralazine with other antihypertensives may potentate the effects

Alcohol, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Alcohol, hydrocodone

The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects

Alcohol, hydromorphone

Alcohol may potentiate the pharmacodynamic effects of hydromorphone. The concomitant use should be avoided

Alcohol, hydroxyzine [2] ---> SmPC of [2] of eMC

Patients should be warned that hydroxyzine may enhance their response to alcohol

Alcohol, idarubicin

Alcohol may enhance the adverse reactions

Alcohol, imipramine [2] ---> SmPC of [2] of eMC

Tricyclic antidepressants may also potentiate the CNS depressant effects of alcohol

Alcohol, indometacin

Enhancement of the adverse effects of the NSAID, especially those of the gastrointestinal tract and CNS

Alcohol, insulin

Possible reduction of the insulin requirements. Alcohol may intensify and prolong the hypoglycaemic effect of insulin

Alcohol, insulin aspart [2] ---> SmPC of [2] of EMA

Alcohol may intensify or reduce the hypoglycaemic effect of insulin.

Alcohol, insulin degludec [2] ---> SmPC of [2] of EMA

Alcohol may intensify or reduce the hypoglycaemic effect of insulin.

Alcohol, insulin degludec/insulin aspart [2] ---> SmPC of [2] of EMA

Alcohol may intensify or reduce the hypoglycaemic effect of insulin.

Alcohol, insulin degludec/liraglutide [2] ---> SmPC of [2] of EMA

Alcohol may intensify or reduce the hypoglycaemic effect of insulin.

Alcohol, insulin detemir [2] ---> SmPC of [2] of EMA

Alcohol may intensify or reduce the hypoglycaemic effect of insulin.

Alcohol, insulin glargin [2] ---> SmPC of [2] of EMA

Alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.

Alcohol, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA

This combination may either potentiate or weaken the blood-glucose-lowering effect of insulin.

Alcohol, insulin glulisin [2] ---> SmPC of [2] of EMA

Possible potentiation or weakening the blood-glucose-lowering activity of insulin.

Alcohol, insulin lispro [2] ---> SmPC of [2] of EMA

Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity

Alcohol, isocarboxazid [2] ---> SmPC of [2] of eMC

With isocarboxazid, as with other drugs acting on the central nervous system, patients should be instructed to avoid alcohol while under treatment, since the individual response cannot be foreseen.

Alcohol, isoniazid

Decreased alcohol tolerance, higher incidence of adverse reactions on the CNS, additive hepatotoxicity

Alcohol, isosorbide dinitrate [2] ---> SmPC of [2] of eMC

Concurrent intake of drugs with blood pressure lowering properties may potentiate the hypotensive effect

Alcohol, isosorbide mononitrate [2] ---> SmPC of [2] of eMC

Alcohol can accentuate cerebral ischaemia associated with postural hypotension.

Alcohol, kebuzone

The co-administration may enhance the effects and increase the risk of gastrointestinal bleeding and ulcer formation

Alcohol, ketamine [2] ---> SmPC of [2] of eMC

The use of ketamine with other central nervous system (CNS) depressants can potentiate CNS depression and/or increase risk of developing respiratory depression.

Alcohol, ketoconazole [2] ---> SmPC of [2] of EMA

Exceptional cases of a disulfiram-like reaction have been reported when ketoconazole was co-administered with alcohol. Patients should be advised against alcohol consumption while on treatment

Alcohol, ketoprofen

Enhancement of the adverse effects of the NSAID, especially those of the gastrointestinal tract and CNS

Alcohol, ketotifen [2] ---> SmPC of [2] of eMC

Ketotifen may potentiate the effects of alcohol

Alcohol, labetalol

The co-administration may increase the bioavailability of labetalol

Alcohol, lacosamide [2] ---> SmPC of [2] of EMA

Although no pharmacokinetic data on the interaction of lacosamide with alcohol are available, a pharmacodynamic effect cannot be excluded.

Alcohol, laropiprant/nicotinic acid [2] ---> SmPC of [2] of EMA

Drinking alcohol or hot drinks or eating spicy foods can enhance the effects of flushing and should therefore be avoided around the time of ingestion of Pelzont.

Alcohol, leflunomide [2] ---> SmPC of [2] of EMA

Due to a potential for additive hepatotoxic effects, it is recommended that alcohol consumption be avoided during treatment with leflunomide.

Alcohol, lercanidipine [2] ---> SmPC of [2] of eMC

Alcohol should be avoided since it may potentiate the effect of vasodilating antihypertensive drugs.

Alcohol, levacetylmethadol [2] ---> SmPC of [2] of EMA

Consumption of alcoholic beverages and medications containing alcohol must be avoided.

Alcohol, levetiracetam [2] ---> SmPC of [2] of EMA

No data on the interaction of levetiracetam with alcohol are available.

Alcohol, levobunolol

The co-administration may have an additive effect

Alcohol, levodopa/carbidopa [2] ---> SmPC of [2] of EMA

In vivo, co-administration of Numient with up to 40% volume-to-volume (v/v) alcohol did not result in dose-dumping of levodopa or carbidopa.

Alcohol, levomepromazine [2] ---> SmPC of [2] of eMC

Alcohol should be avoided.

Alcohol, levomethadone

Enhancement of effects and adverse effects, particularly respiratory depression

Alcohol, levosulpiride

The alcohol intake should be avoided during the treatment

Alcohol, linagliptin/metformin [2] ---> SmPC of [2] of EMA

The concomitant intake of alcohol may enhance the hypoglycemic effect of metformin until hypoglycaemic shock. Alcohol and drugs containing alcohol should be avoided

Alcohol, lisdexamfetamine [2] ---> SmPC of [2] of eMC

There are limited data on the possible interaction with alcohol.

Alcohol, lisuride

The sedative effects of lisuride may be enhanced by alcohol

Alcohol, lofepramine [2] ---> SmPC of [2] of eMC

Effects of lofepramine may be potentiated when administered with CNS depressant substances

Alcohol, lomitapide [2] ---> SmPC of [2] of EMA

Alcohol may increase levels of hepatic fat and induce or exacerbate liver injury. The use of alcohol during lomitapide treatment is not recommended.

Alcohol, lomustine

Increased bleeding risk with decreased thrombocyte count

Alcohol, loprazolam [2] ---> SmPC of [2] of eMC

Concomitant intake with alcohol is not recommended. The sedative effects may be enhanced when the product is used in combination with alcohol.

Alcohol, lorazepam [2] ---> SmPC of [2] of eMC

Lorazepam should not be used together with alcohol (enhanced sedative effects)

Alcohol, lormetazepam

Concomitant use of alcohol is not recommended. The sedative effects may be enhanced when lormetazepam is used in combination with alcohol.

Alcohol, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Potentiation of orthostatic hypotension may occur.

Alcohol, loxapine [2] ---> SmPC of [2] of EMA

Loxapine should be used with caution in combination with alcohol

Alcohol, lurasidone [2] ---> SmPC of [2] of EMA

Given the primary central nervous system effects of lurasidone, lurasidone should be used with caution in combination with other centrally acting medicinal products and alcohol.

Alcohol, manidipine

Like with all vasodilatator, antihypertensive agents, caution is recommended with alcohol is taken concomitant because alcohol may enhance their effects

Alcohol, maprotiline

Maprotiline may enhance the effects of alcohol

Alcohol, medazepam

The sedative effect can be enhanced if medazepam is concomitantly administered with alcohol

Alcohol, medicated sponge [2] ---> SmPC of [2] of EMA

The sealant may be denatured after exposure to solutions containing alcohol, iodine or heavy metals (e.g. antiseptic solutions).

Alcohol, mefruside

The co-administration may increase the antihypertensive effects

Alcohol, melatonin [2] ---> SmPC of [2] of EMA

Alcohol should not be taken with melatonin, because it reduces the effectiveness of melatonin on sleep

Alcohol, melperone

Melperone may enhance the alcohol effect

Alcohol, mephenytoin

The mephenytoin plasma concentrations can decrease (chronic intake) or increase (acute intake)

Alcohol, mepivacaine

Excessive alcohol intake may decrease the sensitivity to local anaesthetics

Alcohol, meprobamate [2] ---> SmPC of [2] of eMC

Concomitant use of alcohol is not recommended. The sedative effects may be enhanced when meprobamate is used in combination with alcohol.

Alcohol, meptazinol [2] ---> SmPC of [2] of eMC

Enhanced sedative and hypotensive effect.

Alcohol, mequitazine

The co-administration may enhance the sedative effect. The alcohol intake should be avoided

Alcohol, mesuximide

Contraindicated

Alcohol, metamizole

Alcohol may change the metamizole effect

Alcohol, metformin ---> SmPC of [canagliflozin/metformin] of EMA

There is increased risk of lactic acidosis in acute alcohol intoxication due to the metformin active substance of this medicinal product. Consumption of alcohol and medicinal products containing alcohol should be avoided.

Alcohol, metformin/saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA

Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in the case of fasting, malnutrition or hepatic impairment. Consumption of alcohol and medicinal products containing alcohol should be avoided

Alcohol, methadone

Enhancement of respiration inhibitor and sedative effect of methadone

Alcohol, methocarbamol [2] ---> SmPC of [2] of eMC

Methocarbamol may potentiate the effects of other central nervous system depressants and stimulants

Alcohol, methotrexate [2] ---> SmPC of [2] of EMA

Regular alcohol consumption and administration of additional hepatotoxic medicinal products increase the probability of hepatotoxic effects of methotrexate. Alcohol consumption must be avoided during treatment with methotrexate.

Alcohol, methyldopa [2] ---> SmPC of [2] of eMC

Concomitant intake of alcohol and methyldopa may enhance the hypotensive effect.

Alcohol, methylphenidate [2] ---> SmPC of [2] of eMC

Alcohol may exacerbate the CNS adverse reactions of psychoactive drugs, including methylphenidate. It is therefore advisable for patients to abstain from alcohol during treatment.

Alcohol, methylprednisolone

Increased risk of gastrointestinal ulcer and bleeding

Alcohol, metoclopramide

Metoclopramide may potentiate the effects of alcohol.

Alcohol, metolazone

The co-administration may enhance the risk of orthostatic hypotension

Alcohol, metoprolol [2] ---> SmPC of [2] of eMC

The concomitant ingestion of alcohol may enhance hypotensive effects.

Alcohol, metronidazole [2] ---> SmPC of [2] of eMC

Patients should be advised not to take alcohol during metronidazole therapy and for at least 48 hours after because of the possibility of a disulfiram-like reaction.

Alcohol, mianserin

Mianserin may enhance the central depressive effect of alcohol. It is recommended no to take alcohol during the treatment

Alcohol, miconazole

Miconazole should not be taken together with alcoholic drinks or medications containing alcohol

Alcohol, midazolam [2] ---> SmPC of [2] of EMA

Alcohol (including alcohol-containing medicinal products may markedly enhance the sedative effect of midazolam. Alcohol intake should be strongly avoided in case of midazolam administration

Alcohol, midodrine

Alcohol may enhance the sympathomimetic effect due to stimulation of the medulla of adrenal gland and release catecholamines

Alcohol, minocycline

Alcohol may increase the metabolism of minocycline and decrease its plasma levels

Alcohol, minoxidil

Alcohol enhances the hypotensive effect of minoxidil

Alcohol, mirtazapine [2] ---> SmPC of [2] of eMC

Mirtazapine may increase the CNS depressant effect of alcohol. It is recommended to avoid alcoholic beverages

Alcohol, mizolastine [2] ---> SmPC of [2] of eMC

In studies with mizolastine, no potentiation of the sedation and the alteration in performance caused by alcohol has been observed.

Alcohol, moexipril [2] ---> SmPC of [2] of eMC

Alcohol enhances the hypotensive effect of moexipril

Alcohol, molsidomine

Alcohol may potentiate the hypotensive effect of molsidomine

Alcohol, morphine [2] ---> SmPC of [2] of eMC

Alcohol may enhance the pharmacodynamic effects of morphine; concomitant use should be avoided.

Alcohol, moxonidine [2] ---> SmPC of [2] of eMC

Moxonidine can potentiate the sedative effect of alcohol

Alcohol, nabilone [2] ---> SmPC of [2] of eMC

Nabilone should be administered with caution to patients who are taking other CNS depressants

Alcohol, nalbuphine

Alcohol enhances the sedative effect of morphinic analgesics. Alcoholic drinks or medications containing alcohol should be avoided

Alcohol, nalmefene [2] ---> SmPC of [2] of EMA

Simultaneous intake of alcohol and Selincro does not prevent the intoxicating effects of alcohol.

Alcohol, naltrexone [2] ---> SmPC of [2] of eMC

There are no known interactions between naltrexone and alcohol.

Alcohol, naltrexone/bupropion [2] ---> SmPC of [2] of EMA

The consumption of alcohol during naltrexone / bupropion treatment should be minimised or avoided.

Alcohol, naphazoline

Possible potentiation of the central depression

Alcohol, naproxen

Enhancement of the adverse effects of the NSAID, especially those of the gastrointestinal tract and CNS

Alcohol, naratriptan [2] ---> SmPC of [2] of eMC

There is no evidence of a pharmacokinetic interaction with alcohol or food.

Alcohol, nebivolol [2] ---> SmPC of [2] of eMC

Co-administration of alcohol did not affect the pharmacokinetics of nebivolol.

Alcohol, neuroleptics ---> SmPC of [chlorpromazine] of eMC

Alcohol enhances the sedative effect of neuroleptics. Association not recommended

Alcohol, niclosamide

The alcohol intake should be avoided

Alcohol, nicomorphine

The co-administration may mutually enhance the sedative and respiratory depressor effect

Alcohol, nicorandil [2] ---> SmPC of [2] of eMC

If nicorandil is used concomitantly with antihypertensive agents or other medicinal products with blood-pressure-lowering effect the blood-pressure-lowering effect may be increased.

Alcohol, nicotinic acid

The alcohol intake should be avoided

Alcohol, nifuratel

Disulfiram-like reaction. The alcohol intake should be avoided

Alcohol, nifuroxazide

The alcohol intake should be avoided

Alcohol, nilutamide

Disulfiram-like reaction. The alcohol intake should be avoided

Alcohol, nitrazepam [2] ---> SmPC of [2] of eMC

Concomitant intake with alcohol should be avoided. The sedative effect may be enhanced when the product is used in combination with alcohol.

Alcohol, nitrofurantoin

Alcohol intake causes disulfiram-like reactions. Contraindicated

Alcohol, nitroglycerine [2] ---> SmPC of [2] of eMC

The risk of hypotension and syncope with use of glyceryl trinitrate may be enhanced by alcohol.

Alcohol, nitroimidazoles

Disulfiram-like reaction. Contraindicated

Alcohol, noradrenaline

The use of noradrenaline with alcohol is not recommended because severe, prolonged hypertension and possible arrhythmias may result

Alcohol, norepinephrine

The use of noradrenaline with alcohol is not recommended because severe, prolonged hypertension and possible arrhythmias may result

Alcohol, nortriptyline [2] ---> SmPC of [2] of eMC

Tricyclic antidepressants may potentiate the CNS depressant effect of alcohol.

Alcohol, NSAID ---> SmPC of [dexibuprofen] of eMC

Enhancement of the adverse effects of the NSAID, especially those of the gastrointestinal tract

Alcohol, olanzapine [2] ---> SmPC of [2] of EMA

Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.

Alcohol, opiates ---> SmPC of [alfentanyl] of eMC

The co-administration may enhance or prolong the respiratory depressant effect of opioid.

Alcohol, opipramol

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Alcohol, oral anticoagulants

The acute/chronic alcohol intake enhances/decreases the anticoagulant effect

Alcohol, organic nitrates ---> SmPC of [nitroglycerine] of eMC

The risk of hypotension and syncope with use of organic nitrates may be enhanced by alcohol.

Alcohol, oxazepam [2] ---> SmPC of [2] of eMC

Concomitant intake of oxazepam with alcohol is not recommended. The sedative effects may be enhanced when oxazepam is used in combination with alcohol.

Alcohol, oxcarbazepine [2] ---> SmPC of [2] of eMC

Caution should be exercised if alcohol is taken in combination with oxcarbazepine therapy, due to a possible additive sedative effect.

Alcohol, oxomemazine

The co-administration may potentiate the sedative effect

Alcohol, oxprenolol [2] ---> SmPC of [2] of eMC

Alcohol effects on the central nervous system have been observed to be additive and it is possible that symptoms such as dizziness may be exaggerated if alcohol and oxprenolol are taken together

Alcohol, oxybutynine [2] ---> SmPC of [2] of EMA

Alcohol may enhance the drowsiness caused by oxybutynine

Alcohol, oxycodone [2] ---> SmPC of [2] of eMC

Alcohol may enhance the pharmacodynamic effects of oxycodone; concomitant use should be avoided.

Alcohol, paliperidone [2] ---> SmPC of [2] of EMA

Paliperidone should be used with caution in combination with alcohol

Alcohol, pantoprazole [2] ---> SmPC of [2] of EMA

No clinically significant interactions were observed

Alcohol, paracetamol

The enzymatic inductor may decrease the plasma levels of paracetamol and increase its hepatotoxicity. Caution is recommended

Alcohol, paroxetine [2] ---> SmPC of [2] of eMC

As with other psychotropic drugs patients should be advised to avoid alcohol use while taking paroxetine.

Alcohol, peanut protein [2] ---> SmPC of [2] of EMA

Alcohol should not be taken for 2 hours before or 2 hours after a dose (see section 4.4, Table 5).

Alcohol, pentaerythritol tetranitrate

The co-administration may potentiate the hypotensive effect

Alcohol, pentazocine [2] ---> SmPC of [2] of eMC

Agents with sedative action can enhance the central depressant effects of pentazocine

Alcohol, pentoxyverine

Pentoxyverine combined with alcohol decreases stronger the psychomotor performance as the individual components

Alcohol, perampanel [2] ---> SmPC of [2] of EMA

Increased levels of anger, confusion, and depression

Alcohol, perazine

The concomitant use of alcohol and perazine may enhance the alcohol effect and cause hypotension

Alcohol, periciazine

Mutual enhancement of effects

Alcohol, perindopril

Increased effect of alcohol

Alcohol, perphenazine [2] ---> SmPC of [2] of eMC

Risk of sedation and/or toxicity when perphenazine is administered with CNS depressants such as alcohol

Alcohol, pethidine [2] ---> SmPC of [2] of eMC

The central depressant effects of pethidine may be potentiated by the concurrent use of other central nervous system depressants

Alcohol, phenelzine [2] ---> SmPC of [2] of eMC

Phenelzine may potentiate the effects of alcohol. Patients should not consume alcoholic drinks

Alcohol, phenobarbital

The co-administration may mutually enhance the CNS depressant effects

Alcohol, phenothiazines [2] ---> SmPC of [2] of eMC

The sedative effects of phenothiazines may be intensified (additively) by alcohol

Alcohol, phenprocoumon

The acute/chronic alcohol intake enhances/decreases the anticoagulant effect

Alcohol, phenylalkylamines

Increased alcohol effect

Alcohol, phenylbutazone

Enhancement of the adverse effects of the NSAID, especially those of the gastrointestinal tract and CNS

Alcohol, phenytoin [2] ---> SmPC of [2] of eMC

Acute alcohol intake may increase phenytoin serum levels while chronic alcoholism may decrease serum levels.

Alcohol, pholcodine [2] ---> SmPC of [2] of eMC

Pholcodine may enhance the sedative effect of central nervous system depressants

Alcohol, pimozide [2] ---> SmPC of [2] of eMC

As with other neuroleptics, pimozide may increase the central nervous system depression produced by other CNS depressant drugs

Alcohol, pindolol [2] ---> SmPC of [2] of eMC

Alcohol may induce increased plasma levels of hepatically metabolised beta-blockers.

Alcohol, pindolol/clopamide [2] ---> SmPC of [2] of eMC

Alcohol may induce increased plasma level of beta-blockers.

Alcohol, pioglitazone/glimepiride [2] ---> SmPC of [2] of EMA

Alcohol intake may potentiate or weaken the hypoglycaemic action of glimepiride in an unpredictable fashion.

Alcohol, pioglitazone/metformin [2] ---> SmPC of [2] of EMA

The concomitant intake of alcohol may enhance the hypoglycemic effect of metformin until hypoglycaemic shock. Alcohol and drugs containing alcohol should be avoided

Alcohol, pipamperone

Potentiation of the depressor effect on the CNS

Alcohol, pipotiazine [2] ---> SmPC of [2] of eMC

The CNS depressant actions of neuroleptic agents may be intensified (additively) by alcohol

Alcohol, piretanide

The hypotensor effect of piretanide may be potentiated

Alcohol, piribedil

The combination of alcohol with piribedil is not recommended

Alcohol, piritramide

The co-administration may enhance the adverse effects of piritramide, particularly respiratory depression

Alcohol, pizotifen [2] ---> SmPC of [2] of eMC

The central effects of alcohol may be enhanced by pizotifen.

Alcohol, podophyllin

Ethyl alcohol enhances the harmful effect of podophyllin

Alcohol, podophyllotoxin

Alcohol can cause strong adverse effects. It is recommended not to take alcohol

Alcohol, porfimer [2] ---> SmPC of [2] of EMA

Compounds that quench active oxygen species or scavenge radicals would be expected to decrease PDT activity.

Alcohol, posaconazole [2] ---> SmPC of [2] of EMA

There are no data on interaction with posaconazole.

Alcohol, prajmalium

Alcohol accelerates the absorption of prajmalium. Alcohol intake should be avoided

Alcohol, pramipexole [2] ---> SmPC of [2] of EMA

Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole.

Alcohol, pravastatine [2] ---> SmPC of [2] of eMC

Caution should be exercised when pravastatin is administered to patients with a history of liver disease or heavy alcohol ingestion.

Alcohol, prazepam

Concomitant use of prazepam and other CNS depressant drugs can mutually enhance the effects

Alcohol, prednisone [2] ---> SmPC of [2] of eMC

The risk of gastrointestinal haemorrhages is increased.

Alcohol, pregabalin [2] ---> SmPC of [2] of EMA

Pregabalin may potentiate the effects of alcohol

Alcohol, primidone [2] ---> SmPC of [2] of eMC

The CNS depressant effect of primidone is additive to those of other CNS depressants

Alcohol, procainamide

Alcohol increases the total-body clearance of procainamide

Alcohol, procarbazine [2] ---> SmPC of [2] of eMC

Intolerance to alcohol (disulfiram-like reaction) may occur.

Alcohol, prochlorperazine [2] ---> SmPC of [2] of eMC

Alcohol should be used with caution

Alcohol, progesterone

Possible increase of progesterone bioavailability

Alcohol, proglumetacine

Enhancement of the adverse effects of the NSAID, especially those of the gastrointestinal tract and CNS

Alcohol, promazine [2] ---> SmPC of [2] of eMC

The concomitant administration of promazine with central nervous system depressants (including alcohol and anaesthetics) may result in accentuation of their effects

Alcohol, promethazine

Alcohol enhances the sedative effect of antihistaminic agents. The concomitant intake of alcohol should be avoided

Alcohol, propofol

Alcohol may enhance the sedative effect

Alcohol, propranolol

Alcohol enhances hypotensive effect, and may increase the plasma levels of propranolol

Alcohol, prothionamide

The intake with alcohol enhances the central stimulant effect

Alcohol, prothipendyl

The combination of prothipendyl and alcohol may mutually enhance the effects

Alcohol, prucalopride [2] ---> SmPC of [2] of EMA

Prucalopride had no clinically relevant effects on the pharmacokinetics of alcohol

Alcohol, pyrazinamide

The co-administration may increase the risk of hepatotoxicity

Alcohol, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS. Alcohol consumption should be avoided

Alcohol, quetiapine [2] ---> SmPC of [2] of eMC

Given the primary central nervous system effects, quetiapine should be used with caution in combination with alcohol.

Alcohol, quinagolide [2] ---> SmPC of [2] of eMC

The tolerability of quinagolide may be reduced by alcohol.

Alcohol, quinapril [2] ---> SmPC of [2] of eMC

Potentiation of orthostatic hypotension may occur.

Alcohol, ramipril [2] ---> SmPC of [2] of eMC

Increased vasodilatation. The antihypertensive effect may increase.

Alcohol, ranitidine

Increased alcohol effect

Alcohol, reboxetine [2] ---> SmPC of [2] of eMC

Reboxetine does not appear to potentiate the effect of alcohol on cognitive functions in healthy volunteers.

Alcohol, repaglinide [2] ---> SmPC of [2] of EMA

Alcohol may enhance and/or prolong the hypoglycaemic effect of repaglinide

Alcohol, reserpine

The co-administration may enhance the CNS depressant effect of reserpine

Alcohol, retigabine [2] ---> SmPC of [2] of EMA

Increase in visual blurring

Alcohol, rifampicin

The alcohol intake increases the incidence of rifampicin-induced hepatotoxicity and the metabolism of rifampicin

Alcohol, risperidone [2] ---> SmPC of [2] of eMC

Risperidone should be used with caution in combination with alcohol due to the increased risk of sedation

Alcohol, ropinirole

It is recommended to avoid alcohol use

Alcohol, rosuvastatin [2] ---> SmPC of [2] of eMC

Rosuvastatin should be used with caution in patients who consume excessive quantities of alcohol

Alcohol, rotigotine [2] ---> SmPC of [2] of EMA

Because of possible additive effects, caution should be advised when patients are taking sedating medicinal products or other CNS (central nervous system) depressants or alcohol in combination with rotigotine.

Alcohol, rufinamide [2] ---> SmPC of [2] of EMA

No data on the interaction of rufinamide with alcohol are available.

Alcohol, salicylates

Increased damage to gastro-intestinal mucosa and prolonged bleeding time due to additive effects of salicylate and alcohol.

Alcohol, saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA

The effects of smoking, diet, herbal products and alcohol use on the pharmacokinetics of saxagliptin, dapagliflozin or fixed dose combination tablet have not been studied.

Alcohol, saxagliptin/metformin [2] ---> SmPC of [2] of EMA

There is increased risk of lactic acidosis in acute alcohol intoxication. Consumption of alcohol and medicinal products containing alcohol should be avoided.

Alcohol, secnidazole

The combination may cause intolerance. Avoid alcohol intake

Alcohol, sedatives

The sedative effect may be enhanced when the product is used in combination with alcohol

Alcohol, selegiline [2] ---> SmPC of [2] of eMC

Concomitant use of selegiline and alcohol should be avoided.

Alcohol, sertraline [2] ---> SmPC of [2] of EMA

The concomitant use of sertraline and alcohol is not recommended.

Alcohol, sevoflurane [2] ---> SmPC of [2] of eMC

Medicinal products and compounds that increase the activity of isoenzyme CYP2E1 may increase the metabolism of sevoflurane and lead to significant increases in plasma fluoride concentrations.

Alcohol, sibutramine [2] ---> SmPC of [2] of eMC

The consumption of alcohol is not compatible with the recommended dietary measures as a general rule.

Alcohol, sildenafil [2] ---> SmPC of [2] of EMA

Sildenafil did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/dl.

Alcohol, simvastatine [2] ---> SmPC of [2] of eMC

Simvastatin should be used with caution in patients who consume substantial quantities of alcohol.

Alcohol, sitagliptin/metformin [2] ---> SmPC of [2] of EMA

Consumption of alcohol and medicinal products containing alcohol should be avoided

Alcohol, sodium oxybate [2] ---> SmPC of [2] of EMA

The combined use of alcohol with sodium oxybate may result in potentiation of the central nervous system-depressant effects of sodium oxybate. Patients should be warned against the use of any alcoholic beverages in conjunction with sodium oxybate.

Alcohol, sodium valproate [2] ---> SmPC of [2] of eMC

Alcohol intake is not recommended during treatment with valproate

Alcohol, solutions for sealant [2] ---> SmPC of [2] of EMA

Possible denaturation of tissue sealing

Alcohol, sotalol

The concomitant use of alcohol and sotalol should be avoided due to the possibility of ventricular arrhythmias

Alcohol, spirapril

Increased hypotensive and alcohol effect

Alcohol, spironolactone

Alcohol may enhance an orthostatic hypotension

Alcohol, SSRI ---> SmPC of [fluoxetine] of eMC

In formal testing, fluoxetine did not raise blood alcohol levels or enhance the effects of alcohol. However, the combination of SSRI treatment and alcohol is not advisable.

Alcohol, sufentanil [2] ---> SmPC of [2] of EMA

The concomitant use of CNS depressants including barbiturates, benzodiazepines, neuroleptics or other opioids, halogen gases or other non-selective CNS depressants (e.g. alcohol) may enhance respiratory depression.

Alcohol, sulfonylureas

Alcohol intake may potentiate or weaken the hypoglycaemic effect

Alcohol, sulphamides

Possible disulfiram-like reaction. The alcohol intake should be avoided

Alcohol, sulphonamides

Possible disulfiram-like reaction. The alcohol intake should be avoided

Alcohol, sulpiride [2] ---> SmPC of [2] of eMC

Alcohol enhances the sedative effect of neuroleptics. Association not recommended

Alcohol, sultiame

Possible disulfiram-like reaction. The alcohol intake should be avoided

Alcohol, sumatriptan [2] ---> SmPC of [2] of eMC

Studies in healthy subjects show that sumatriptan does not interact with alcohol

Alcohol, sympathomimetics

Alcohol may enhance the sympathomimetic effect due to stimulation of the medulla of adrenal gland and release catecholamines

Alcohol, tadalafil [2] ---> SmPC of [2] of EMA

Alcohol concentrations were not affected by co-administration with tadalafil

Alcohol, tapentadol [2] ---> SmPC of [2] of eMC

The co-administration may enhance the sedative effect of tapentadol

Alcohol, telmisartan [2] ---> SmPC of [2] of EMA

An orthostatic hypotension may be aggravated by alcohol.

Alcohol, telmisartan/amlodipine [2] ---> SmPC of [2] of EMA

An orthostatic hypotension may be aggravated by alcohol.

Alcohol, temazepam [2] ---> SmPC of [2] of eMC

Temazepam should not be used together with alcohol (enhanced sedative effects)

Alcohol, temsirolimus [2] ---> SmPC of [2] of EMA

The amount of alcohol in this medicinal product may alter the effects of other medicines. Harmful for those suffering from alcoholism.

Alcohol, terbutaline

Alcohol may enhance the cardiac and circulatory regulator sympathomimetics effects of terbutaline

Alcohol, teriflunomide [2] ---> SmPC of [2] of EMA

The medicinal product should be used with caution in patients who consume substantial quantities of alcohol.

Alcohol, terizidone

Alcohol increases the possibility and risk of epileptic seizures

Alcohol, tetrabenazine

The co-administration of tetrabenazine with CNS depressant drugs may have an additive sedative effect

Alcohol, tetracyclic antidepressant [2] ---> SmPC of [2] of eMC

Alcohol intake is not advisable during antidepressant treatment

Alcohol, tetrazepam

The co-administration may enhance mutually the effects. It is recommended not to take alcohol

Alcohol, thalidomide [2] ---> SmPC of [2] of EMA

Thalidomide has sedative properties thus may enhance the sedative effects of other medicinal products

Alcohol, thiamine

Decreased absorption of thiamine

Alcohol, thiazides ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Alcohol, thiethylperazine

The co-administration may potentiate the CNS depressant effect

Alcohol, thioridazine

Phenothiazines may enhance the alcohol effects

Alcohol, thioxanthenes

Additive effect

Alcohol, thrombin ---> SmPC of [human fibrinogen/human thrombin] of EMA

Similar to comparable products or thrombin solutions, the product may be denatured after exposure to solutions containing alcohol

Alcohol, tianeptine

It is recommended not to take alcohol

Alcohol, tiapride [2] ---> SmPC of [2] of eMC

Alcohol enhances the sedative effect of neuroleptics. Association not recommended

Alcohol, tilidine

Enhancement of CNS depressant effect, particularly respiratory depression

Alcohol, timolol [2] ---> SmPC of [2] of eMC

Alcohol induces increased plasma levels of hepatically metabolised beta blockers

Alcohol, tinidazole [2] ---> SmPC of [2] of eMC

Concurrent use of tinidazole and alcohol may produce a disulfiram-like reaction and should be avoided.

Alcohol, tiopronin

It is recommended not to take alcohol

Alcohol, tizanidine [2] ---> SmPC of [2] of eMC

Alcohol may enhance the sedative action of tizanidine.

Alcohol, tolbutamide [2] ---> SmPC of [2] of eMC

Increased hypoglycaemic effects have occurred or might be expected

Alcohol, topiramate [2] ---> SmPC of [2] of eMC

It is recommended that topiramate not be used concomitantly with alcohol

Alcohol, trabectedin [2] ---> SmPC of [2] of EMA

Alcohol consumption must be avoided during treatment with trabectedin due to the hepatotoxicity of the medicinal product

Alcohol, tramadol [2] ---> SmPC of [2] of eMC

Concomitant administration of tramadol with other centrally acting drugs including alcohol may potentiate CNS depressant effects.

Alcohol, tramazoline

Possible enhancement of the central depression

Alcohol, trandolapril

Alcohol enhances the hypotensive effect

Alcohol, trandolapril/verapamil [2] ---> SmPC of [2] of eMC

Alcohol enhances the hypotensive effect

Alcohol, tranylcypromine [2] ---> SmPC of [2] of eMC

Tranylcypromine may potentiate the effects of alcohol

Alcohol, trazodone [2] ---> SmPC of [2] of eMC

Trazodone intensifies the sedative effects of alcohol. Alcohol should be avoided during trazodone therapy.

Alcohol, triamterene [2] ---> SmPC of [2] of eMC

The co-administration of triamterene and alcohol may enhance the hypotensive effect

Alcohol, triamterene/hydrochlorothiazide

The antihypertensive effect of triamterene/hydrochlorothiazide may be enhanced by alcohol

Alcohol, triazolam

Alcohol intake should be avoided during treatment with triazolam because alcohol may potentiate the triazolam action in an unpredictable fashion.

Alcohol, tricyclic antidepressant ---> SmPC of [imipramine] of eMC

Tricyclic antidepressants may potentiate the CNS depressant effects of alcohol

Alcohol, trifluoperazine

Alcohol enhances the sedative effect of neuroleptics. Alcohol intake should be avoided during the treatment

Alcohol, trimipramine [2] ---> SmPC of [2] of eMC

Tricyclic antidepressants potentiate the central nervous depressant action of alcohol.

Alcohol, tropisetron

It is recommended to avoid alcohol use during treatment

Alcohol, urapidil

The antihypertensive effect of urapidil may be enhanced with alcohol intake

Alcohol, valproic acid [2] ---> SmPC of [2] of eMC

Alcohol may exacerbate the hepatic toxicity of valproate

Alcohol, vardenafil [2] ---> SmPC of [2] of EMA

When vardenafil and alcohol were taken together, vardenafil did not potentiate the effects of alcohol on blood pressure and heart rate and the pharmacokinetics of vardenafil were not altered.

Alcohol, varenicline [2] ---> SmPC of [2] of EMA

There is limited clinical data on any potential interaction between alcohol and varenicline. There have been post marketing reports of increased intoxicating effects of alcohol in patients treated with varenicline.

Alcohol, venlafaxine [2] ---> SmPC of [2] of eMC

As with all CNS-active substances, patients should be advised to avoid alcohol consumption.

Alcohol, verapamil [2] ---> SmPC of [2] of eMC

Plasma concentration of alcohol may be increased

Alcohol, verteporfin [2] ---> SmPC of [2] of EMA

Possible quenching of the activated oxygen species generated by verteporfin, resulting in decreased verteporfin activity.

Alcohol, vilazodone

It is recommended to avoid alcohol use while taking SSRI

Alcohol, vildagliptin/metformin [2] ---> SmPC of [2] of EMA

There is increased risk of lactic acidosis in acute alcohol intoxication due to the metformin active substance. Consumption of alcohol and medicinal products containing alcohol should be avoided.

Alcohol, vitamin B1

Decreased absorption of thiamine

Alcohol, vortioxetine [2] ---> SmPC of [2] of EMA

Alcohol intake is not advisable during antidepressant treatment

Alcohol, warfarin [2] ---> SmPC of [2] of eMC

Acute ingestion of a large amount of alcohol may inhibit the metabolism of warfarin and increase INR. Conversely, chronic heavy alcohol intake may induce the metabolism of warfarin. Moderate alcohol intake can be permitted.

Alcohol, xipamide [2] ---> SmPC of [2] of eMC

The dosage of other hypotensive drugs may require adjustment when used in conjunction with xipamide

Alcohol, zaleplon [2] ---> SmPC of [2] of EMA

Concomitant intake with alcohol is not recommended. The sedative effect may be enhanced when the product is used in combination with alcohol.

Alcohol, zimeldine

It is recommended to avoid alcohol use while taking SSRI

Alcohol, ziprasidone

The possibility of an additive or potentiating effect with CNS depressants should be considered.

Alcohol, zolpidem [2] ---> SmPC of [2] of eMC

The sedative effect may be enhanced when the product is used in combination with alcohol.

Alcohol, zopiclone [2] ---> SmPC of [2] of eMC

The sedative effect of zopiclone may be enhanced when used in combination with alcohol, concomitant use is therefore not recommended.

Alcohol, zotepine

The co-administration may cause a mutual potentiation of effects

Alcohol, zuclopenthixol [2] ---> SmPC of [2] of eMC

Zuclopenthixol enhances the response to alcohol